ENTPD5 and colorectal carcinoma: MacCarthy et al. reported that abnormal expression of ENTPD5 in human colorectal carcinoma cells could influence ATP levels and the resistance to oxaliplatin, a colorectal cancer-relevant chemotherapeutic agent [27].